
GSK Consumer Healthcare, a unit of druggernaut GlaxoSmithKline, makes and sells a wide range of over-the-counter drugs, oral care products, and nutritionals. Brands and products range from oral care (Aquafresh toothpaste) to dermatology (Zovirax cold sore medication), with all kinds of analgesics (Panadol), gastrointestinal remedies (Tums), and smoking-cessation products (Nicoderm) in between. GSK Consumer Healthcare also makes a variety of vitamins and natural remedies, as well as the weight loss product alli.

Omrix Biopharmaceuticals helps keep blood in its place in the operating room. The company develops biosealants derived from human plasma to control bleeding during surgical procedures. The biosealants contain naturally occurring proteins that clot and adhere to tissue. Johnson & Johnson's Ethicon subsidiary markets and distributes these products under the names Evicel in the US and Quixil in Europe. Omrix's Evithrom thrombin product was developed with Ethicon primarily for neurosurgery. The FDA has approved both for hemostasis (minimizing blood loss) during surgery. Omrix was acquired by Johnson & Johnson in 2008 and became part of the Ethicon division.

MicroIslet, Inc. is a biotechnology company engaged in the research, development and commercialization of technologies in the field of transplantation therapy for people with conditions requiring cell-based replacement treatments, with a focus on type 1, or insulin-dependent diabetes. Islet transplantation technology, licensed from Duke University, along with the Company's developments, constitutes methods for isolating, culturing, cryopreservation, and immuno-protection (microencapsulation) of islet cells. MicroIslet intends to continue its research and development efforts and to introduce products to the market.

BioSpecifics Technologies Corp. company was founded in 1957 and is headquartered in Lynbrook, New York. BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase for multiple indications in the United States. The company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase known as XIAFLEX for clinical indications in dupuytren's disease, peyronie's disease, and frozen shoulder. The XIAFLEX is under phase IIb clinical trial for the treatment of peyronie's disease. BioSpecifics Technologies also focuses on the development of collagenase for various other clinical indications, including lipomas and cellulite.

ZymoGenetics, Inc. company was founded in 1981 and is headquartered in Seattle, Washington. ZymoGenetics, Inc., a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections. Its products include RECOTHROM, a recombinant thrombin, which is a topical hemostatic agent used for the control of moderate bleeding during surgical procedures. The company's product candidates in clinical development stages include PEG-IFN-l, a pegylated version of the IFN-l1 protein, which is in Phase Ib clinical trials for the treatment of viral infections and autoimmune diseases; IL-21 for the treatment of metastatic melanoma and metastatic renal cell carcinoma; IL-21 monoclonal antibody (mAb) to treat inflammatory diseases; and IL-31 mAb for the treatment of atopic dermatitis and inflammatory diseases. Its out-licensed product candidates include atacicept for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; Augment Bone Graft for orthopedic fracture and other bone defects; rFactor XIII for congenital factor XIII deficiency, cardiac surgery, and cancer related bleeding; Fibroblast growth factor-18 for osteoarthritis; IL-17 receptor C for inflammatory diseases; and IL-20 and IL-22 receptor subunit alpha for psoriasis. The company also offers out-licensed commercial products comprising Novolin and insulin analogs for diabetes; NovoSeven for the treatment of hemophilia; Regranex for wound healing; GEM 21S for periodontal defects; GlucaGen for hypoglycemia and gastrointestinal motility inhibition; and Cleactor for treatment of myocardial infarction. ZymoGenetics has collaboration agreements with Bayer Schering Pharma AG; Bristol-Myers Squibb Company; and Merck Serono S.A.

Established in 1989 as the commercial arm of the Scottish Crop Research Institute, MRS assists UK agricultural and plant biotechology scientists develop their ideas into marketable products. Profits earned from its efforts are plowed back into the research institution. MRS labs offer pathogen testing, plant analysis, and consulting services. MRS works with companies interested in licensing technologies that the researchers use to breed high-quality varieties of potatoes, soft fruits, barley, and other agricultural products.

RegeneRx Biopharmaceuticals was founded in 1982 and is headquartered in Rockville, Maryland. RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of novel molecules to promote tissue and organ repair. The company develops its product candidates based on Thymosin beta 4 (Tb4), a 43 amino acid peptide. Its product candidates in clinical development include RGN-137, a topically applied gel for chronic dermal wounds; RGN-259, a sterile topical eye drop for ophthalmic wounds; and RGN-352, a parenteral formulation for the treatment of patients with an acute myocardial infarction, or heart attack. Its pre-clinical development product includes RGN-457, an inhaled formulation of Tb4 targeting cystic fibrosis and other pulmonary diseases. The company has a strategic partnership with Defiante Farmaceutica L.d.a. for the development and marketing of RGN-137, and certain indications relating to RGN-352 primarily in Europe.

Nymox Pharmaceutical was founded in 1989 and is based in St. Laurent, Canada. Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs and diagnostic devices. Its products include NicAlert and TobacAlert tests that use urine or saliva to detect use of and exposure to tobacco products; and AlzheimAlert, a urinary test that aids physicians in the diagnosis of Alzheimer's disease. The company's products under development comprises NX-1207, which is in phase III trial for the treatment of enlarged prostate; NXC-4720, an antibacterial agent that is in laboratory trials for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat, and other food and drink products, as well as for the treatment of urinary tract and other bacterial infections in humans; and Statins, a class of commonly prescribed cholesterol lowering drugs to treat, prevent, or reduce the risk of Alzheimer's disease. It is also in the preclinical stage of developing therapeutic products for oncological indications; and has various diagnostic markers and technologies, including a patented platform for point-of-care testing.

Simplexity Health (formerly Cell Tech International) hopes that the algae growing in the fountain of youth is the secret. More specifically, the company scrapes up Aphanizomenon flos-aquae, a type of blue-green algae, out of Upper Klamath Lake, and stirs it into nutritional supplements, body care products, and nutrition bars. Calling it Super Blue Green Algae, the company's product line includes digestive aids, weight loss supplements, antioxidants, and powdered drink mixes. Simplexity Health sells its products through a multi-level, direct marketing program using a network of independent associates.

Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania. Lannett Company, Inc. develops, manufactures, markets, and distributes generic versions of pharmaceutical products in the United States. The company manufactures and/or sells various prescription products. Its product portfolio includes acetazolamide, baclofen, and bethanechol chloride tablets; amantadine gel capsules; butalbital, aspirin, and caffeine with codeine phosphate, danazol, and clindamycin HCl capsules; cocaine topical solution; and dicyclomine tablets and capsules. Lannett company's products also comprise digoxin, dipyridamole, doxycycline, doxycycline hyclate, esterified estrogen and methyltestoterone, hydrochlorothiazide, hydromorphone HCl, and levothyroxine sodium tablets; morphine sulfate oral solutions; and OB-natal one gel capsules. In addition, its products consist of pilocarpine HCl, primidone, probenecid, terbutaline sulfate, and unithroid tablets; oxycodone HCl oral solution; rifampin and ursodiol capsules; and phentermine HCl tablets and capsules. Lannett Company markets its products under the brand names of Diamox, Symmetrel, Lioresal, Urecholine, Fiorinal, Cleocin, Danocrine, Bentyl, Lanoxin, Persantine, Adoxa, Periostat, Estratest, Hydrodiuril, Dilaudid, Levoxyl/ Synthroid, Roxanol, PrimaCare ONE, Roxicodone, Adipex-P, Fastin, Salagen, Mysoline, Benemid, Rifadin, Brethine, Actigall, and Fiorinal w/ Codeine #3. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.







.webp)
.webp)
.webp)
.webp)
.webp)






